Cerebrolysin improves sciatic nerve dysfunction in a mouse model of diabetic peripheral neuropathy.

Dong HY, Jiang XM, Niu CB, Du L, Feng JY, Jia FY

Neural regeneration research1 Jan 2016Cited by 14 (Europe PMC)

PMID26981106PMCIDPMC4774211DOI10.4103/1673-5374.175063PepBankPUB-26981106

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, Cerebrolysin increased the number of myelinated sciatic nerve fibers.
In plain wordsIn mice with diabetes, Cerebrolysin increased the number of myelinated sciatic nerve fibers.
Peptide
Cerebrolysin
Outcome
IncreaseMyelinated nerve fiber number
Study
mousen: not reported in source
Type 2 diabetes mellitus model
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
1.80, 5.39 or 8.98 mL/kg · intraperitoneal · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
Our results demonstrated that the number, diameter and area of myelinated nerve fibers increased in the sciatic nerves of these mice after administration of Cerebrolysin.
1 context sentence(design, population, supporting numbers)
Summary · context
Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days.
Report a problemFND-2698110601
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, Cerebrolysin increased the diameter of myelinated sciatic nerve fibers.
In plain wordsIn mice with diabetes, Cerebrolysin increased the diameter of myelinated sciatic nerve fibers.
Peptide
Cerebrolysin
Outcome
IncreaseMyelinated nerve fiber diameter
Study
mousen: not reported in source
Type 2 diabetes mellitus model
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
1.80, 5.39 or 8.98 mL/kg · intraperitoneal · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
Our results demonstrated that the number, diameter and area of myelinated nerve fibers increased in the sciatic nerves of these mice after administration of Cerebrolysin.
1 context sentence(design, population, supporting numbers)
Summary · context
Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days.
Report a problemFND-2698110602
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, Cerebrolysin increased the area of myelinated sciatic nerve fibers.
In plain wordsIn mice with diabetes, Cerebrolysin increased the area of myelinated sciatic nerve fibers.
Peptide
Cerebrolysin
Outcome
IncreaseMyelinated nerve fiber area
Study
mousen: not reported in source
Type 2 diabetes mellitus model
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
1.80, 5.39 or 8.98 mL/kg · intraperitoneal · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
Our results demonstrated that the number, diameter and area of myelinated nerve fibers increased in the sciatic nerves of these mice after administration of Cerebrolysin.
1 context sentence(design, population, supporting numbers)
Summary · context
Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days.
Report a problemFND-2698110603
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, Cerebrolysin dose-dependently increased inclined-plane slope angle compared with untreated diabetic mice.
In plain wordsIn mice with diabetes, Cerebrolysin increased inclined-plane slope angle compared with untreated diabetic mice.
Peptide
Cerebrolysin
Outcome
IncreaseInclined-plane slope angle
Study
mousen: not reported in source
Type 2 diabetes mellitus model
Comparator
Untreated diabetic mice
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
1.80, 5.39 or 8.98 mL/kg · intraperitoneal · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
The results of several behavioral tests showed that Cerebrolysin dose-dependently increased the slope angle in the inclined plane test (indicating an improved ability to maintain body position)
1 context sentence(design, population, supporting numbers)
Summary · context
Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days.
Report a problemFND-2698110604
05AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, Cerebrolysin prolonged tail-flick latency compared with untreated diabetic mice.
In plain wordsIn mice with diabetes, Cerebrolysin prolonged tail-flick latency compared with untreated diabetic mice.
Peptide
Cerebrolysin
Outcome
IncreaseTail-flick latency
Study
mousen: not reported in source
Type 2 diabetes mellitus model
Comparator
Untreated diabetic mice
Outcome group
Pain · Nervous system and cognition
Studied dose
1.80, 5.39 or 8.98 mL/kg · intraperitoneal · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
prolonged tail-flick latency and foot-licking time (indicating enhanced sensitivity to thermal and chemical pain, respectively, and reduced pain thresholds)
1 context sentence(design, population, supporting numbers)
Summary · context
Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days.
Report a problemFND-2698110605
06AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, Cerebrolysin prolonged foot-licking time compared with untreated diabetic mice.
In plain wordsIn mice with diabetes, Cerebrolysin prolonged foot-licking time compared with untreated diabetic mice.
Peptide
Cerebrolysin
Outcome
IncreaseFoot-licking time
Study
mousen: not reported in source
Type 2 diabetes mellitus model
Comparator
Untreated diabetic mice
Outcome group
Pain · Nervous system and cognition
Studied dose
1.80, 5.39 or 8.98 mL/kg · intraperitoneal · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
prolonged tail-flick latency and foot-licking time (indicating enhanced sensitivity to thermal and chemical pain, respectively, and reduced pain thresholds)
1 context sentence(design, population, supporting numbers)
Summary · context
Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days.
Report a problemFND-2698110606
07AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, Cerebrolysin increased the sciatic nerve function index compared with untreated diabetic mice.
In plain wordsIn mice with diabetes, Cerebrolysin increased the sciatic nerve function index compared with untreated diabetic mice.
Peptide
Cerebrolysin
Outcome
IncreaseSciatic nerve function index
Study
mousen: not reported in source
Type 2 diabetes mellitus model
Comparator
Untreated diabetic mice
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
1.80, 5.39 or 8.98 mL/kg · intraperitoneal · 10 consecutive daysAs given in this study (mouse).
Source sentences
Summary
and increased an index of sciatic nerve function in diabetic mice compared with those behavioral results in untreated diabetic mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days.
Report a problemFND-2698110607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.